Qi Bian, Shu Wang, Zimin Song, Fang Liu, Muqing Cao, Nan Yang, Jun Ying, Jia-Syuan Hu, Xinyuan Xiong, Huiqin Zhu, Jun Wu, Jie Yang, Xiaonan Wang, Shunli Shen, Xuxu Sun
{"title":"Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice","authors":"Qi Bian, Shu Wang, Zimin Song, Fang Liu, Muqing Cao, Nan Yang, Jun Ying, Jia-Syuan Hu, Xinyuan Xiong, Huiqin Zhu, Jun Wu, Jie Yang, Xiaonan Wang, Shunli Shen, Xuxu Sun","doi":"10.1097/hep.0000000000001422","DOIUrl":null,"url":null,"abstract":"Background & Aims: Intrahepatic cholangiocarcinomas (ICCs) are aggressive liver tumors with high heterogeneity and limited therapeutic options. Although traditionally thought to arise from biliary cells, recent findings suggest that hepatocytes may also serve as a cellular origin for ICC. However, the mechanisms underlying hepatocyte malignant transformation and ICC initiation remain poorly understood. Approach and Results: We employed oncogene-driven and chemically induced ICC murine models, along with cellular models, to recapitulate the transformation of hepatocytes into ICC. Our findings demonstrate that mature hepatocytes undergo a significant hyperpolyploid state during ICC initiation. Hyperpolyploidy promotes aberrant cell division and chromosomal instability, accelerating hepatocyte transformation and ICC onset. Furthermore, we identified the chromatin remodeling factor <jats:italic toggle=\"yes\">Arid1a</jats:italic> as a critical suppressor of hyperpolyploidy. <jats:italic toggle=\"yes\">Arid1a</jats:italic> deficiency disrupts mitotic machinery at the centrosome, driving hyperpolyploidization and ICC tumorigenesis. Conclusions: Hepatocytes can transform into ICC through a process involving hyperpolyploidizaiton. This study offers new insights into the pathogenesis of ICC, particularly in patients harboring frequent <jats:italic toggle=\"yes\">ARID1A</jats:italic> mutations.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"11 1","pages":""},"PeriodicalIF":12.9000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/hep.0000000000001422","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background & Aims: Intrahepatic cholangiocarcinomas (ICCs) are aggressive liver tumors with high heterogeneity and limited therapeutic options. Although traditionally thought to arise from biliary cells, recent findings suggest that hepatocytes may also serve as a cellular origin for ICC. However, the mechanisms underlying hepatocyte malignant transformation and ICC initiation remain poorly understood. Approach and Results: We employed oncogene-driven and chemically induced ICC murine models, along with cellular models, to recapitulate the transformation of hepatocytes into ICC. Our findings demonstrate that mature hepatocytes undergo a significant hyperpolyploid state during ICC initiation. Hyperpolyploidy promotes aberrant cell division and chromosomal instability, accelerating hepatocyte transformation and ICC onset. Furthermore, we identified the chromatin remodeling factor Arid1a as a critical suppressor of hyperpolyploidy. Arid1a deficiency disrupts mitotic machinery at the centrosome, driving hyperpolyploidization and ICC tumorigenesis. Conclusions: Hepatocytes can transform into ICC through a process involving hyperpolyploidizaiton. This study offers new insights into the pathogenesis of ICC, particularly in patients harboring frequent ARID1A mutations.
期刊介绍:
HEPATOLOGY is recognized as the leading publication in the field of liver disease. It features original, peer-reviewed articles covering various aspects of liver structure, function, and disease. The journal's distinguished Editorial Board carefully selects the best articles each month, focusing on topics including immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases, liver cancer, and drug metabolism.